Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Korosho Compiles SOP for Revising Package Inserts
March 1, 2010
- New Method Proposed to Show Equivalence of Generics and Original Drugs
March 1, 2010
- CDFS Recommends Approval for Vectibix from Takeda
March 1, 2010
- Eliminate Distinction between Clinical Research and Trials, Introduce IND System: Prof. Kawakami
March 1, 2010
- Shionogi Applies for Rapiacta for Pediatric Use
March 1, 2010
- Consider Ethnic Diversity at Early Stage of Drug Development: Dr Iwasaki
March 1, 2010
- Olmetec Approved for Children, Adolescents Aged 6-16
March 1, 2010
- Takeda Begins PIII Program for Hematide in Japan
March 1, 2010
- Kissei Returns Marketing Right for Cinalong to UCB
March 1, 2010
- Toyama Chemical Initiates PII Trial for T-705 in the US
March 1, 2010
- Maruho to Market Actosin from April
March 1, 2010
- Nippon Shinyaku, Actelion to Codevelop Macitentan for PAH
March 1, 2010
- Takashi Kodama to Be Reelected JPA President
March 1, 2010
- Medipal Ties Up with Medical Ikkou
March 1, 2010
- Dr Hakui Elected as President of Osaka Medical Association
March 1, 2010
- DSP Aims at Increasing Overseas Sales to 50% of Total Sales in FY2014
March 1, 2010
- FDA Approves Crestor for Preventive Purposes: AZ
March 1, 2010
- Korosho Asks Local Governments to Increase Stock of Relenza
March 1, 2010
- Promoting Oncology Products with Small Number of Elite MRs: Dr Adachi of Eli Lilly
March 1, 2010
- Tykerb Approved for Use in Combination with Femara: GSK
March 1, 2010
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…